The Effects of Quercefit® and Ubiqsome™ in Mitigating Inflammation and Promoting Metabolic Health
1 other identifier
interventional
60
1 country
1
Brief Summary
The goal of this clinical trial is to learn if Quercefit® or Ubiqsome™ can improve markers of healthy aging, blood sugar control, and heart health in older adults. It will also learn about the safety of these supplements. The main questions it aims to answer are:
- 1.Do Quercefit® or Ubiqsome™ improve blood sugar, cholesterol, and markers of aging compared to a placebo?
- 2.What side effects, if any, do participants have while taking these supplements?
- 3.Take their assigned capsules (Quercefit®, Ubiqsome™, or placebo) twice daily for 12 weeks
- 4.Go to a preferred clinic at the start and end of the study for a fasting blood draw
- 5.Grip strength testing (using a device mailed to them)
- 6.Online surveys about fatigue and quality of life
- 7.Report any side effects and keep track of supplement use
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Aug 2026
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 27, 2026
CompletedStudy Start
First participant enrolled
August 1, 2026
CompletedFirst Posted
Study publicly available on registry
August 12, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
August 1, 2028
August 12, 2026
August 1, 2026
2 years
July 27, 2026
August 10, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Inflammaging (CIMKDM)
A fasting venous blood sample will be collected via venipuncture by a certified phlebotomist at the participant's designated Labcorp location following a minimum 10-hour overnight fast. Samples will be processed at a central laboratory using standardized assay protocols. Inflammaging (CIMKDM) is a biologically derived estimate of age, expressed in years, calculated from a composite of inflammatory biomarkers reflecting chronic low-grade inflammation and immune system activation. Higher values indicate a greater degree of inflammation-related biological aging.
Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Phenotypic Age
A fasting venous blood sample will be collected via venipuncture by a certified phlebotomist at the participant's designated Labcorp location following a minimum 10-hour overnight fast. Samples will be processed at a central laboratory. Phenotypic Age is a composite biomarker-based estimate of biological aging, expressed in years, derived from chronological age and nine clinical chemistry and hematological markers (albumin, creatinine, glucose, C-reactive protein, lymphocyte percentage, mean cell volume, red cell distribution width, alkaline phosphatase, and white blood cell count). Higher values relative to chronological age indicate accelerated biological aging.
Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Secondary Outcomes (35)
Grip Strength
Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Insulin Resistance (HOMA-IR)
Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Insulin Sensitivity (QUICKI)
Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
High-Sensitivity C-Reactive Protein (hs-CRP)
Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Cortisol
Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
- +30 more secondary outcomes
Study Arms (3)
Group 1 (Quercefit® only)
EXPERIMENTAL500 mg Quercefit® per day, administered as one 250 mg capsule taken twice daily (morning and evening)
Group 2 (Ubiqsome™ only)
ACTIVE COMPARATOR300 mg Ubiqsome™ per day, administered as one 150 mg capsule taken twice daily (morning and evening)
Group 3 (Placebo)
PLACEBO COMPARATOROne placebo capsule taken twice daily (morning and evening)
Interventions
Natural compound found in foods like apples and onions that may help reduce inflammation and support overall health.
Substance made by the body that helps produce energy in cells and also acts as an antioxidant to support heart and overall health.
Eligibility Criteria
You may qualify if:
- Males and females aged 50 to 75 years
- Participants who meet the requirements of a sedentary lifestyle. Meaning, subjects who do not meet the World Health Organization's (WHO) minimum activity guidelines, of at least 150 minutes of moderate-intensity activity, or, 75 minutes of vigorous-intensity activity a week, plus muscle-strengthening activities at least 2 days per week. Of importance, incidental physical activity (eg, walking to work, household activities) would not meet the standard of being physically active according to WHO guidelines (McKay et al., 2021).
- BMI of \> or equal to 25.00kg/m²
- Individuals with \> or equal to 5 score relative to high risk for prediabetes as defined by the CDC (https://www.cdc.gov/prediabetes/takethetest)
- Free of all other chronic diseases.
- Not currently using glucose-lowering agents or insulin.
- Able to read and write in English
- Willing to maintain a habitual diet, supplement routine, and avoid other lifestyle changes during the study period.
- During the study, participants agree not to take any other supplement that can impact glucose or insulin regulation.
- During the study, participants agree not to take any other supplement that can impact cardiovascular health, inflammatory status, or anti-aging supplements
- Willing to have blood drawn
- Must have access to a reliable internet connection and a computer to complete remote assessments
You may not qualify if:
- Unwilling to have blood drawn
- Unwilling to swallow pills
- Pregnancy or has breast fed within 3 months prior to enrollment
- Current use of prescription medication or drug that impacts Glucose or Insulin metabolism (including direct insulin treatment) within the past 6-months
- Current use of Quercetine or CoQ10 supplements within the past 4-weeks
- History or current alcohol or drug abuse
- Known diagnosis of any chronic cardiovascular, metabolic, endocrine, or renal disease outside of prediabetes as listed above.
- Has significant concurrent illnesses (controlled or uncontrolled), such as lupus, hepatitis B/C, HIV, serious mental health illness such as dementia or schizophrenia; psychiatric hospitalization in the past two years, or other conditions, which in the opinion of the investigator, such condition might be aggravated as a result of treatment
- Developmental disability or cognitive impairment that would preclude adequate comprehension of the informed consent form and/or ability to follow study subject requirements and/or record the necessary study measurements.
- History of cardiovascular disease (i.e., myocardial infarction, hypertension, hypercholesterolemia, peripheral vascular disease, other)
- History of neurological disorders (Parkinson's, Amyotrophic lateral sclerosis, epilepsy, spinal cord injury resulting in inability to use upper extremities, other.)
- History of gastrointestinal disorders that could lead to uncertain absorption of the study supplements (i.e., inflammatory bowel disease, ulcerative colitis, -Crohn's disease, colostomy, or eating disorder)
- History of kidney or liver disease
- History of metabolic disorders (diabetes, metabolic syndrome, other)
- History of current malignancy/cancer
- +3 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
The Applied Science and Performance Institute
Tampa, Florida, 33634, United States
Related Publications (7)
Sood B, Patel P, Keenaghan M. Coenzyme Q10. 2024 Jan 30. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK531491/
PMID: 30285386RESULTRiva A, Ronchi M, Petrangolini G, Bosisio S, Allegrini P. Improved Oral Absorption of Quercetin from Quercetin Phytosome(R), a New Delivery System Based on Food Grade Lecithin. Eur J Drug Metab Pharmacokinet. 2019 Apr;44(2):169-177. doi: 10.1007/s13318-018-0517-3.
PMID: 30328058RESULTDi Pierro F, Rabbani F, Tareen M, Nigar R, Khan A, Zerbinati N, Tanda ML, Cazzaniga M, Bertuccioli A, Falasca P, Damiani G, Villanova N. Potential pharmacological effect of Quercetin Phytosome in the management of hyperuricemia: results from real-life clinical studies. Front Nutr. 2025 Feb 7;12:1519459. doi: 10.3389/fnut.2025.1519459. eCollection 2025.
PMID: 39990611RESULTHan MK, Barreto TA, Martinez FJ, Comstock AT, Sajjan US. Randomised clinical trial to determine the safety of quercetin supplementation in patients with chronic obstructive pulmonary disease. BMJ Open Respir Res. 2020 Feb;7(1):e000392. doi: 10.1136/bmjresp-2018-000392.
PMID: 32071149RESULTMcKay AKA, Stellingwerff T, Smith ES, Martin DT, Mujika I, Goosey-Tolfrey VL, Sheppard J, Burke LM. Defining Training and Performance Caliber: A Participant Classification Framework. Int J Sports Physiol Perform. 2022 Feb 1;17(2):317-331. doi: 10.1123/ijspp.2021-0451. Epub 2022 Dec 29.
PMID: 34965513RESULTLiu Z, Kuo PL, Horvath S, Crimmins E, Ferrucci L, Levine M. A new aging measure captures morbidity and mortality risk across diverse subpopulations from NHANES IV: A cohort study. PLoS Med. 2018 Dec 31;15(12):e1002718. doi: 10.1371/journal.pmed.1002718. eCollection 2018 Dec.
PMID: 30596641RESULTLevine ME, Lu AT, Quach A, Chen BH, Assimes TL, Bandinelli S, Hou L, Baccarelli AA, Stewart JD, Li Y, Whitsel EA, Wilson JG, Reiner AP, Aviv A, Lohman K, Liu Y, Ferrucci L, Horvath S. An epigenetic biomarker of aging for lifespan and healthspan. Aging (Albany NY). 2018 Apr 18;10(4):573-591. doi: 10.18632/aging.101414.
PMID: 29676998RESULT
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Jacob Wilson, PhD
The Applied Science and Performance Institute
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 27, 2026
First Posted
August 12, 2026
Study Start
August 1, 2026
Primary Completion (Estimated)
August 1, 2028
Study Completion (Estimated)
August 1, 2028
Last Updated
August 12, 2026
Record last verified: 2026-08
Data Sharing
- IPD Sharing
- Will not share